MetLife Investment Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

MetLife Investment Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,464	Closed	-$55.6K	–	2999
2023 Q2	$55.6K	Buy	21,464 +13,459	+168%	+$48K	﹤0.01%	2889
2023 Q1	$32.7K	Sell	8,005 -10,296	-56%	-$47.6K	﹤0.01%	2749
2022 Q4	$91.9K	Hold	18,301	–	–	﹤0.01%	2626
2022 Q3	$239K	Hold	18,301	–	–	﹤0.01%	2166
2022 Q2	$235K	Hold	18,301	–	–	﹤0.01%	2202
2022 Q1	$279K	Buy	18,301 +6,636	+57%	+$104K	﹤0.01%	2136
2021 Q4	$207K	Hold	11,665	–	–	﹤0.01%	2032
2021 Q3	$245K	Hold	11,665	–	–	﹤0.01%	1960
2021 Q2	$230K	Hold	11,665	–	–	﹤0.01%	2073
2021 Q1	$339K	Hold	11,665	–	–	﹤0.01%	1744
2020 Q4	$353K	Hold	11,665	–	–	﹤0.01%	1667
2020 Q3	$186K	Hold	11,665	–	–	﹤0.01%	1906
2020 Q2	$230K	Hold	11,665	–	–	﹤0.01%	1819
2020 Q1	$144K	Hold	11,665	–	–	﹤0.01%	1875
2019 Q4	$216K	Buy	+11,665	New	+$171K	﹤0.01%	1936

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MetLife Investment Management's NGM Position: Q3 2023 in Review

MetLife Investment Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 21,464 shares — an estimated $55.6K sold.

MetLife Investment Management first reported a position in NGM in Q4 2019 and held it in 15 quarters. The position peaked at $353K in Q4 2020. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

MetLife Investment Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
MetLife Investment Management sold 21,464 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $55.6K.
MetLife Investment Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 15 quarters.
MetLife Investment Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $353K in Q4 2020.
94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.